ライフサイエンスコーパス: adverse

1 with an increased relative risk of serious, adverse 90-day outcomes, the incidence of clinically sig

2 le, Long Evans rats experienced a battery of adverse adolescent experiences (n = 12), while controls

3 Adverse associations between pollen and multiple outcome

4 in our review, 21 focused on diabetes, 15 on adverse birth outcomes, 8 on cardiovascular disease, 3 e

5 ir pollution and meteorological variables on adverse birth outcomes.

6 d significantly higher success but not major adverse cardiac event rates compared with inexperienced

7 of coronary bypass surgery to a reduction of adverse cardiac outcomes.

8 Adverse cardiac remodeling after myocardial infarction (

9 At 5 years, the incidence of major adverse cardiovascular and cerebrovascular events was hi

10 0.73 [0.69-0.76] for CABG) and 5-year major adverse cardiovascular events (C-index=0.65 [0.61-0.69]

11 Secondary outcomes included major adverse cardiovascular events (death, myocardial infarct

12 r has been shown to reduce the risk of major adverse cardiovascular events (MACE) compared with aspir

13 ry disease (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those

14 d, the mechanisms through which NSAIDs cause adverse cardiovascular events are not entirely understoo

15 tudied associations between LGE presence and adverse cardiovascular events in patients with dilated c

16 2016 were 0.73 (95% CI, 0.62-0.84) for major adverse cardiovascular events, 0.92 (95% CI, 0.85-1.00)

17 or arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous th

18 ardial infarction, stroke, and overall major adverse cardiovascular or cerebrovascular events were re

19 therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among pa

20 was the PM(2.5) species most associated with adverse cardiovascular outcomes.

21 tions between marijuana and a broad range of adverse cardiovascular risks.

22 sterol and triglycerides are associated with adverse changes in cardiac structure and function, in pa

23 study, we aimed to describe trajectories of adverse childhood experiences and relate these to overal

24 odevelopmental model traces the pathway from adverse childhood experiences and stress to disruption o

25 s of children and responses to the impact of adverse childhood experiences, and (c) whether services

26 productivity and resistance to pathogens in adverse climates.

27 dinal focus on disease management (to reduce adverse clinical outcomes and disease progression among

28 We described clinical characteristics and adverse clinical outcomes of U.S. invasive Hia cases det

29 The effects of these adverse conditions on plant productivity are becoming ev

30 of abdominal and pelvic surgery, leading to adverse consequences.

31 The occurrence of adverse drug reactions and somnolence were observed in 1

32 , unsustainable agricultural production, and adverse ecological impacts.

33 are due to physical multimorbidity, and its adverse economic effect in population groups in China.

34 contrast, linear MR analyses demonstrated an adverse effect of increasing DBP increments on CVD outco

35 suggests that type I and especially the less adverse effect-prone type III IFN are good candidates fo

36 ucted to determine whether BPAR mediated the adverse effects between ethnicity and outcomes.

37 difficile infection, and antibiotic-related adverse effects necessitating change in therapy.

38 rs, which are devoid of the neuropsychiatric adverse effects observed with brain-penetrant CB1R block

39 ted serious adverse events occurred, and few adverse effects occurred after in-community treatment wi

40 Adverse effects of breast cancer treatment can negativel

41 Many studies have estimated the adverse effects of climate change on crop yields, howeve

42 on factor (TF) that mediates protection from adverse effects of hypertonicity by increasing transcrip

43 The most common adverse effects of isradipine were edema and dizziness.

44 However, the adverse effects of mixed shifts on perceptions of staffi

45 to flame retardants (FRs) is associated with adverse effects on human health.

46 t cortical development and have long-lasting adverse effects on neurodevelopmental outcome.

47 icals present in the environment, those with adverse effects on the endocrine system are referred to

48 Psychological stress has adverse effects on various human diseases, including tho

49 nt that include the alleviation of long-term adverse effects require a deeper understanding of the ge

50 these new treatments are accompanied by new adverse effects that radiologists need to know.

51 No vaccine-related serious adverse effects were found in the dose-ranging study in

52 occi (VRE) colonization after receiving OVP, adverse effects, and cost of OVP.

53 Mexiletine 0.1 and 0.5 uM had no adverse effects, but did not reduce VF incidence.

54 ity, specificity, preterm delivery, maternal adverse effects, congenital birth defects, childhood can

55 have high analgesic potency and low risk of adverse effects, particularly no abuse liability.

56 ts that result in significant toxicities and adverse effects.

57 tment may be ineffective and associated with adverse effects.

58 den may account for important health-related adverse effects.

59 h dose-escalated RT, pattern of failure, and adverse effects.

60 All medications have adverse effects.

61 nodal level and external failures due to an adverse environment, and develop a pair approximation an

62 predicted the drug effects and occurrence of adverse episodes, even though the population was optimiz

63 he control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]).

64 pneumonia (OR 5.37, 95% CI: 1.17-24.65), any adverse event (OR 1.55, 95% CI: 1.03-2.33), adverse even

65 ts (OR 2.65, 95% CI: 1.04-6.80), any serious adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adve

66 the most common grade 3-4 study drug-related adverse event (two [1%] of 157 patients, both grade 3),

67 Subdeltoid bursitis has been reported as an adverse event after intramuscular vaccination in the del

68 e for the development of this immune-related adverse event and to ultimately predict or prevent its d

69 >=75 years were also more likely to have an adverse event attributable to TB medication and were mor

70 BCAR) within 60 weeks after transplantation; adverse event coding was centralised.

71 Combined adverse event data and BCAR episodes from all six CTG tr

72 At least 1 serious adverse event developed in 12 patients (24%) in the ritu

73 to lack or loss of efficacy in 74 patients, adverse event in 34 patients, and sustained quiescence i

74 one death resulting from a treatment-related adverse event in the subcutaneous daratumumab group (feb

75 B medication and were more likely to have an adverse event later in therapy.

76 ciated with similar hypertrophy severity and adverse event rates as observed with truncating variants

77 We compare adverse event rates associated with IV iron vs red cell

78 Serious adverse event rates could not be determined with meta-an

79 gan reducing payments to hospitals with high adverse event rates.

80 b, osimertinib) by data mining using the FDA adverse event reporting system (AERS) database, and by c

81 e data at week 16-17, or sooner if a serious adverse event requiring knowledge of the study drug occu

82 2W group had at least one treatment-emergent adverse event.

83 Anemia was the main adverse event.

84 Serious adverse events (AEs) occurred in 10% of imipenem/relebac

85 Grade 3 or 4 treatment-related adverse events (AEs) occurred in 75% and 87% of patients

86 nducted a disproportionality analysis of the adverse events (AEs) of EGFR-TKIs (gefitinib, erlotinib,

87 There were 277 mild adverse events (AEs) recorded through the passive pharma

88 Rates of adverse events (AEs) were similar between both groups.

89 Detailed study of ophthalmic immune-related adverse events (AEs), including determination of inciden

90 l reactions (LRs) and systemic events (SEs), adverse events (AEs), serious AEs, newly diagnosed chron

91 rding to the Common Terminology Criteria for Adverse Events (CTCAE), version 5, and its relationship

92 rated by the Common Terminology Criteria for Adverse Events (CTCAE; v4.03) classification.

93 ommonly evoke a wide range of immune-related adverse events (irAEs) that can affect any organ system

94 -limiting toxicity (DLT) from immune-related adverse events (irAEs).

95 Treatment-related adverse events (mainly mild or moderate local reactions)

96 eason (OR 2.61, 95% CI: 1.38-4.96) or due to adverse events (OR 2.65, 95% CI: 1.04-6.80), any serious

97 associated with a risk of procedural serious adverse events (SAE) and exposure to ionizing radiation.

98 The total incidence of AE and serious adverse events (SAE) was calculated.

99 comes, culture-conversion rates, and serious adverse events (SAEs) during treatment.

100 oints were solicited/unsolicited and serious adverse events (SAEs), biochemical/hematological paramet

101 Grade >=3 treatment-related adverse events (TRAEs) were experienced by 72% of patien

102 decreases in LOS had a higher risk of severe adverse events [1.22 (1.11-1.34)] and death [1.17 (1.04-

103 Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%)

104 xisting evidence for serious and non-serious adverse events after ivermectin exposure in pregnant wom

105 k PE, there were no deaths or device-related adverse events and a significant reduction in right vent

106 ella use was associated with higher rates of adverse events and costs.

107 (HCC) because of the potential for profound adverse events and large variations in survival outcome.

108 lerated a total of 17 FUS treatments with no adverse events and neither cognitive nor neurological wo

109 There were no drug-related serious adverse events and no treatment-related deaths.

110 Adverse events and pharmacokinetic measurements were ass

111 Adverse events are common after ICU discharge to hospita

112 No grade 3 or higher adverse events are seen.

113 and 2 and treatment-associated grade 3 or 4 adverse events at least possibly related to study treatm

114 There was no difference in adverse events between randomised groups.

115 d with an increased risk of death or serious adverse events compared with allopurinol.

116 Adverse events consisted primarily of elevated liver tes

117 Adverse events could be minimised by using non-isoniazid

118 the placebo group (with 6 infectious serious adverse events developing among 4 patients [9%]).

119 Proportions of patients with adverse events did not differ significantly among groups

120 adverse event (OR 1.55, 95% CI: 1.03-2.33), adverse events due to decreased appetite (OR 3.56, 95% C

121 Adverse events from these agents might affect the abilit

122 biological and pharmacokinetic measures, and adverse events graded 2 or higher.

123 Serious adverse events in the lower-threshold group included con

124 Serious adverse events included 1 suicide attempt, related to co

125 The frequency of adverse events leading to treatment discontinuation was

126 nts for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis.

127 Costs contained drugs, monitoring and adverse events measured in US Dollars.

128 was safe, with no treatment-related serious adverse events observed.

129 Results: No adverse events occurred after injection of (18)F-SKI.

130 Serious adverse events occurred equally between groups.

131 Nonfatal serious adverse events occurred in 12/72 (16.7%) in the oral gro

132 Grade 3 to 5 treatment-related adverse events occurred in 5.7% (n = 6) of patients.

133 Grade 3-4 adverse events occurred in 71 (91%) of 78 patients in th

134 Adverse events occurred in 89.3% of patients, the most c

135 No severe adverse events occurred in any of the procedures.

136 No intervention-related serious adverse events occurred, and few adverse effects occurre

137 e rituximab group (with 9 infectious serious adverse events occurring among 6 patients [12%]) versus

138 The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reporte

139 Overall, 21 adverse events of grade 3 or higher were recorded.

140 The incidence of dental and skin adverse events of special interest was higher with the 1

141 ide information on the time profile of these adverse events or reflect the continuous, lower grade sy

142 ary outcome was safety, defined as number of adverse events per total number of sessions.

143 duced durable responses and had a manageable adverse events profile in patients with relapsed or refr

144 e tone averages (PTA), and procedure-related adverse events rated by the Common Terminology Criteria

145 event (OR 2.30, 95% CI: 1.18-4.48), serious adverse events related to abnormal liver function tests

146 response rates and potential immune-related adverse events remain two major challenges.

147 Most adverse events resulted only in symptoms (77%) and 36% w

148 No adverse events such as hypo/hyperpigmentation, skin infe

149 ous adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the LY-CoV5

150 eloped a preliminary approach to predict 135 adverse events using post-market safety data from market

151 The frequency of participants experiencing adverse events was higher in the hydroxychloroquine grou

152 The number of serious adverse events was similar in both groups and unrelated

153 ntage of participants with local or systemic adverse events was similar in the two groups.

154 e most frequently reported grade 3 or higher adverse events were abnormal blood chemistry results (33

155 Progression-free survival (PFS), OS, and adverse events were also assessed.

156 tivity, endothelial cell count, and possible adverse events were assessed at least 12 months postoper

157 No serious adverse events were attributed to dihydroartemisinin-pip

158 All patients had engraftment, and adverse events were consistent with effects of the prepa

159 The most common grade 3-4 adverse events were febrile neutropenia (22 [66%]), bloo

160 The most common grade 3 or 4 adverse events were hypertension (88 [27%] of 332 patien

161 All treatment-related adverse events were mild or moderate in severity and sim

162 Most adverse events were mild.

163 Systemic adverse events were more common after the second vaccina

164 Serious adverse events were more common with systematic treatmen

165 Adverse events were more common with zoledronic acid tha

166 Adverse events were mostly mild and equally distributed

167 The most common treatment-related grade 3-4 adverse events were neutropenia (15 [50%] of 30 patients

168 The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patient

169 The most common grade 3-4 adverse events were raised gamma-glutamyltransferase (13

170 was well tolerated and no study drug-related adverse events were recorded.

171 Two serious adverse events were reported - both resolved without seq

172 Solicited adverse events were reported by 44% of vaccine recipient

173 Adverse events were reported in 108 (69%) of 156 patient

174 Adverse events were reported in 58.4% of patients; most

175 Serious adverse events were reported in five (3%) of 156 patient

176 Eight serious adverse events were reported with capsular release and t

177 No severe vaccine-related adverse events were reported.

178 Cumulative rates of serious adverse events were similar in TAK-003 (4.0%) and placeb

179 mmon (>=20% patients in any group) grade 3-4 adverse events were thrombocytopenia (33 [42%] of 78, 26

180 Serious procedure-related adverse events were uncommon.

181 There were no unexpected adverse events with (177)Lu-PSMA retreatment.

182 There were decreased Optimizer-related adverse events with the 2-lead system compared with the

183 points were safety (assessed by incidence of adverse events) and pharmacokinetics (assessed by serum

184 Adverse events, although mild, were more common in both

185 fety end points were device related death or adverse events, and major bleeding within 72 hours after

186 the probable cause for grade 3-4 hematologic adverse events, as they occurred before CAR-NKT cell inf

187 patients (21%) with grade >=3 immune-related adverse events, consisting of asymptomatic laboratory ab

188 les that include the incidence of high-grade adverse events, defined by the Common Terminology Criter

189 fined by the Common Terminology Criteria for Adverse Events, do not provide information on the time p

190 Incidences of adverse events, drug continuation, implantable cardiover

191 cacy, there is also the potential for severe adverse events, including cytokine release syndrome (CRS

192 or trial registration, and poor reporting of adverse events, methods of sequence generation and alloc

193 (32%) patients experienced grade 3 or worse adverse events, of which the most common were anaemia (f

194 afety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events

195 y and simultaneously identify immune-related adverse events, there are several challenges in interpre

196 at were included had no reported significant adverse events, therefore, these 10 nonpharmacological i

197 y a stepwise method to capture all available adverse events, we first extracted data on myelodysplast

198 36 individuals had 63 serious adverse events, which included 25 suicide attempts and 2

199 ificant between-group differences in serious adverse events.

200 gression were conducted to assess risk of GI adverse events.

201 0-mug dose group reported one or more severe adverse events.

202 tibodies, which often inflict immune-related adverse events.

203 nal management, with a lower risk of serious adverse events.

204 ded cumulative incidence rates for (serious) adverse events.

205 linically relevant treatment-related serious adverse events.

206 to identify the risk factors associated with adverse events.

207 r two of the four patients developed serious adverse events.

208 s associated with an increased risk of major adverse events.

209 n-free survival and was associated with more adverse events.

210 ICU discharge date to identify and classify adverse events.

211 s associated with transient mild to moderate adverse events.

212 difference in positive microbial cultures or adverse events.

213 (3.3%) vs 9 (6.1%) experienced other serious adverse events.

214 (9%) patients had serious treatment-related adverse events.

215 fined by the Common Terminology Criteria for Adverse Events.

216 Four subjects withdrew due to adverse events.

217 rs for discontinuation due to inefficacy and adverse events.

218 s (n = 5) had treatment-related grade 3 or 4 adverse events.

219 of study drug in terms of treatment-emergent adverse events.

220 ty, as measured by the occurrence of serious adverse events.

221 occurring, yet preventable hospital-acquired adverse events.

222 n follow-up of 6.6 years, there were 8 major adverse events: 6 relapses, 1 treatment-related death (f

223 (v) psychological characteristics, and (vi) adverse experiences during adulthood.

224 ive N deposition on Earth's surface leads to adverse feedbacks on ecosystems and humans.

225 This study identified evidence of diverse adverse functional and morphologic cardiac manifestation

226 associated with increased HIV risk and other adverse health and psychosocial outcomes.

227 The prospect of EDCs causing adverse health effects in humans and wildlife has led to

228 ysis of PR, the widespread UOGD could induce adverse health effects to residents living close to UOGD

229 e and is of concern due to associations with adverse health effects.

230 on atmospheric pollutants and known to cause adverse health effects.

231 nventional natural gas development (UNGD) to adverse health has implicated air pollution and stress p

232 ociations between particle radioactivity and adverse health outcomes, including changes in blood pres

233 ened beverage (SSB) consumption is linked to adverse health outcomes.

234 y (CTPA) rates in subgroups at high risk for adverse imaging outcomes, including young women and chil

235 cipation in the community also mitigated the adverse impact of housing damage on functional status, s

236 nal to age, such that frailty had a stronger adverse impact on younger patients.

237 t of human societies and an important, often adverse, influence on ecosystems.

238 ntrinsic variability and carries a memory of adverse intrauterine conditions experienced during the l

239 tension, which is associated with new-onset, adverse kidney-related outcomes.Study registered with Au

240 revascularization are at high risk for major adverse limb and cardiovascular events.

241 primary patency rate and Freedom from major adverse limb events (F-MALE).

242 r events, 0.92 (95% CI, 0.85-1.00) for major adverse limb events, 0.60 (95% CI, 0.48-0.74) for myocar

243 the best decisions for cooperation are risk-adverse (low sensitivity, high specificity).

244 [>=12% increase in LVEDV only]; and group 4: adverse LV remodeling [>=12% increase in both LVESV and

245 Here we show that Dysf(-/-) mice develop adverse LV remodeling following I/R injury secondary to

246 [changes in LVEDV and LVESV <12%]; group 3: adverse LV remodeling with compensation [>=12% increase

247 or NICU mothers should be explored to reduce adverse maternal health outcomes.

248 Thus, our data point to potential adverse neurobehavioral consequences of exposure to sacc

249 The adverse neurocognitive sequelae following clinical radio

250 a plausible pathogenic mechanism explaining adverse obstetrical outcomes in antiphospholipid syndrom

251 Long-term cognitive decline is an adverse outcome after major surgery associated with incr

252 entify the encephalopathic babies at risk of adverse outcome may accelerate the development of neurop

253 We propose an adverse outcome pathway, where the oxidation of metaboli

254 e no differences in adjusted 1-year risks of adverse outcomes across hospital quartiles of potent P2Y

255 Persistent smoking may cause adverse outcomes among patients with cancer.

256 s are highly susceptible to COVID-19-induced adverse outcomes and complications.

257 with higher risk of disease progression and adverse outcomes from coronavirus disease 2019 (COVID-19

258 Obesity may contribute to adverse outcomes in coronavirus disease 2019 (COVID-19).

259 aregiving, identified caregivers at risk for adverse outcomes, and evaluated a wide range of interven

260 tion rates, without subsequent reductions in adverse outcomes, can indicate overuse.

261 with IDSA severity, but not with subsequent adverse outcomes.

262 elivery and expansion and is associated with adverse outcomes.

263 nt relationship, and caregiving itself, with adverse outcomes.

264 en noted (n = 156, 53.4%) as contributing to adverse outcomes.

265 itiated deliveries, and to prevent perinatal adverse outcomes.

266 nate potential (CHIP) and is associated with adverse outcomes.

267 ng this at-risk population can help mitigate adverse outcomes.

268 botype 027 associate with severe disease and adverse outcomes.

269 , 49 and 17 months for 0, 1 to 2, and 3 to 4 adverse pathology, respectively (P < 0.001), and 76, 51,

270 amic use up to and beyond 9 days without any adverse physiological consequence.

271 m the AURORA multisite longitudinal study of adverse post-traumatic neuropsychiatric sequelae (APNS)

272 e intake relative to total energy intake and adverse pregnancy outcomes using targeted maximum likeli

273 Maternal hypertension is associated with adverse pregnancy outcomes, including fetal growth restr

274 ociations between antenatal IPT exposure and adverse pregnancy outcomes, maternal TB, all-cause morta

275 Iron disorders are associated with adverse pregnancy outcomes, yet iron homeostatic mechani

276 falciparum in pregnancy is a major cause of adverse pregnancy outcomes.

277 triction (FGR) and pre-eclampsia are severe, adverse pregnancy outcomes.

278 portional hazards models to adjust for known adverse prognostic factors.

279 Adverse prognostic features of the cohort included short

280 al stress exposure (PNSE) increases risk for adverse psychiatric and behavioral outcomes in offspring

281 Peanut allergy imposes an adverse psychosocial impact on patients and caregivers,

282 17 serious adverse reactions occurred in 11 patients, and there was

283 Adverse reactions occurred in a quarter of all patients,

284 radiologic manifestations of immune-mediated adverse reactions than in those without radiologic manif

285 zinamide was responsible for the majority of adverse reactions.

286 ions of the mAb could be used to reduce such adverse reactions.

287 bortus Results from this study indicate that adverse reproductive outcomes can occur as sequelae of c

288 Traffic proximity has been associated with adverse respiratory health outcomes.

289 and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001).

290 of disease as defined by the presence of an adverse-risk karyotype, the presence of secondary acute

291 se both diets reduced urinary sodium without adverse safety or quality of life signals, a larger tria

292 onselective, pan-HDAC inhibitors, exhibiting adverse side effects at therapeutic doses.

293 due to its potential specificity and lack of adverse side effects when compared to more traditional m

294 This release profile can be used to limit adverse side effects, reduce dosing frequency, and poten

295 These include (i) adverse socioeconomic and psychosocial experiences durin

296 atus was the only significant MRI factor for adverse survival (HR 2.36 (1.54-3.61) for OS, 2.37 (1.47

297 we identified a subgroup of patients with an adverse TME associated with 17 fewer months of progressi

298 meliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles.

299 In addition to adverse trends in stroke-related morbidity and mortality

300 on of pro-fibrotic signaling pathways before adverse ventricular remodeling and progression of HF.